Halozyme Therapeutics, Inc.
HALO Healthcare Biotechnology
Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 44.1%, free cash flow grew 141.2% and total debt rose 42.2%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
Follow HALO
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Cash and Short Term Investments |
231.00 | 318.62 | 142.82 | 701.96 |
+8 more quarters Free account |
Receivables |
455.83 | 457.99 | 441.27 | 346.04 | |
Inventory |
137.14 | 155.47 | 176.48 | 185.80 | |
Total current assets |
933.02 | 1,003.04 | 825.21 | 1,328.75 | |
Property, Plant, Equpment (Net) |
84.27 | 82.23 | 82.14 | 71.42 | |
Goodwill and Intangible Assets (Total) |
1,504.18 | 1,534.28 | 1,561.83 | 765.37 | |
Long-term assets (Other) |
55.94 | 53.18 | 56.15 | 55.70 | |
Total non-current assets |
1,644.38 | 1,669.68 | 1,700.12 | 892.48 | |
Total Assets |
2,577.41 | 2,672.72 | 2,525.32 | 2,221.23 | |
Accounts Payable |
23.61 | 14.10 | 20.90 | 15.36 | |
Accrued Expenses |
111.86 | 140.37 | 156.19 | 111.18 | |
Current Part of Debt |
208.97 | 208.74 | — | 710.69 | |
Total current liabilities |
344.44 | 363.21 | 177.09 | 837.23 | |
Long Term Debt (Total) |
1,937.68 | 1,935.90 | 2,142.63 | 800.07 | |
Long Term Tax Liability (Deferred) |
49.06 | 47.53 | 42.92 | 8.22 | |
Non-current Liabilities (Other) |
102.68 | 106.45 | 113.86 | 71.80 | |
Total non-current liabilities |
2,089.43 | 2,089.87 | 2,299.42 | 880.09 | |
Total liabilities |
2,433.87 | 2,453.08 | 2,476.51 | 1,717.32 | |
Additional Paid In Capital |
— | 27.39 | 12.00 | 23.91 | |
Common Stock (Net) |
0.11 | 0.12 | 0.12 | 0.12 | |
Retained Earnings |
151.26 | 204.84 | 54.79 | 502.15 | |
Common Equity (Total) |
143.54 | 219.64 | 48.81 | 503.92 | |
Shareholders Equity (Total) |
143.54 | 219.64 | 48.81 | 503.92 | |
Shareholders Equity and Liabilities (Total) |
2,577.41 | 2,672.72 | 2,525.32 | 2,221.23 | |
Shares (Common) |
114.04 | 118.52 | 117.78 | 117.52 | |
Shareholders Equity (Tangible) |
(1,360.63) | (1,314.64) | (1,513.01) | (261.45) | |
Net Debt |
1,915.65 | 1,826.02 | 1,999.81 | 808.79 | |
Total Debt |
2,146.65 | 2,144.64 | 2,142.63 | 1,510.76 |